
- Telehealth Visits
- Insurance plan information

Daniel H. Lowenstein, MD
Neurology • Epilepsy NeurologyExecutive Vice Chancellor and Provost- Telehealth Visits
- Insurance plan information



Daniel H. Lowenstein, MD
Neurology • Epilepsy NeurologyExecutive Vice Chancellor and Provost- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Daniel H. Lowenstein, an internationally known epileptologist, is executive vice chancellor and provost of UCSF. He has served as director of the UCSF Epilepsy Center and president of the American Epilepsy Society. He joined UCSF after serving as dean of medical education at Harvard Medical School, where he earned his medical degree.
Lowenstein spent many years at UCSF as professor of neurology and director of the Epilepsy Research Laboratory in the School of Medicine. A prolific writer and scholar, he has received virtually every teaching award given by UCSF's School of Medicine. His interests include the molecular and cellular changes in neural networks following seizure activity and injury, the genetic basis of epilepsy, and therapy for abnormally prolonged seizures known as status epilepticus.
Education & training
Board certification
- Neurology, American Board of Psychiatry/Neurology-Psychiatry
Residency
- Neurology, UCSF Graduate Medical Education
Internship
- Pediatrics, UCSF Graduate Medical Education
Degree
- MD, Harvard Medical School
My expertise
Specialties
Clinical Trials query: q=health_gateway_id_ss%3A%28%22251%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%22251%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.